Comparing Two Brain Stimulation Targets for Tremor-Dominant Parkinson's Disease
Compares deep brain stimulation at two brain sites in tremor-dominant Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Directional PSA Versus STN DBS for TD-PD
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07700862, who can take part
Where in China
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT07700862
- Record updated
- 14 July 2026
- Original description
The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.Read full original descriptionShow less
Directional Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial
The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.
Inclusion: diagnosis of idiopathic Parkinson's disease; tremor-dominant subtype in the off-medication condition; modified Hoehn-Yahr scale of 2 to 4 in the off-medication condition; receiving regular anti-parkinsonian drugs for more than 6 weeks; good compliance and written informed consent provided.
Exclusion: History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery; Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent; Other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data; Atypical parkinsonism; Presence of anatomical abnormalities in the target region; Clinically significant medical history that would increase pre-/post-operative complications.